Streetbeat News

Stock Prices

KRP

Analyst ratings for Kimbell Royalty Partners (NYSE:KRP) have shown a mix of bullish to bearish sentiments over the past three months, with a recent average price target of $20.75, indicating a 4.25% decrease from the previous target of $21.67. The company's financial health is highlighted by strong revenue growth, net margin, and ROA, but challenges in ROE and a sound debt management structure are noted. Analysts' adjustments in ratings and price targets reflect changing market conditions and company performance.

Portfolio Pulse from Benzinga Insights

April 05, 2024 | 9:01 pm

PLUG

In the last three months, 17 analysts have published ratings on Plug Power (NASDAQ:PLUG), showing a diverse range of perspectives. The recent ratings indicate a shift towards a more bearish outlook, with the latest 30-day period seeing an increase in bearish ratings. The average 12-month price target for PLUG has decreased to $4.61 from $5.72, indicating a 19.41% decrease. Analysts have adjusted their ratings and price targets based on changing market dynamics and company performance, reflecting varying expectations for Plug Power's future value.

Portfolio Pulse from Benzinga Insights

April 05, 2024 | 9:00 pm

DOGEUSD

Despite a 15% weekly drop in Dogecoin (DOGE) value, whale activity and bullish signals from analysts suggest a positive outlook. Significant transfers of DOGE between wallets and exchanges, along with a dormant whale's activity, have been noted. Analysts predict a parabolic run for DOGE, supported by a bullish crossover in its MACD signal.

Portfolio Pulse from Khyathi Dalal

April 05, 2024 | 8:57 pm

ADAUSD

AVAXUSD

XRPUSD

Grayscale Digital Large Cap Fund has liquidated all its Cardano (ADA) holdings, causing ADA to tumble 10% over the week. The fund, with $579 million in assets, had 1.62% of its portfolio in ADA. It has added Avalanche (AVAX) and Ripple (XRP) to its portfolio, now comprising Bitcoin, Ethereum, Solana, XRP, and Avalanche. Despite a drop in ADA's price, a significant portion of holders remain profitable, and the project continues to develop, with a weekly report highlighting milestones.

Portfolio Pulse from Khyathi Dalal

April 05, 2024 | 8:42 pm

AGEN

Agenus Inc announced that its common stock is expected to trade on the Nasdaq Capital Market on a split-adjusted basis starting April 12, 2024.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 8:35 pm

AC

Associated Capital Group, Inc. (AC) announced a preliminary Q1 book value of $42.67 to $42.87 per share, an increase from $42.11 at the end of 2023 and $41.30 at the end of Q1 2023. Detailed financial results will be released in May.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 8:35 pm

ELTX

Elicio Therapeutics, Inc. (NASDAQ:ELTX) announced it will present updated clinical and preclinical data at the AACR Annual Meeting. The data includes positive outcomes from the AMPLIFY-201 Phase 1 study of ELI-002, showing significant T cell responses in patients with mKRAS-driven cancers. Additionally, preclinical studies of ELI-007 and ELI-008 demonstrated substantial immune responses compared to conventional vaccines. ELTX plans to present initial ELI-002 7P clinical data in Q2 2024.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 8:34 pm

LOCL

Local Bounti Corporation (NYSE:LOCL), an indoor agriculture company, received a notice from the NYSE on April 3, 2024, for not meeting the Minimum Market Capitalization Standard. The company's market capitalization and stockholders' equity were both below $50 million. Local Bounti plans to submit a compliance plan within 45 days and has 18 months to meet the NYSE's standards. The notice does not immediately affect its stock listing, and the company is exploring options to regain compliance.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 8:33 pm

AGEN

Agenus Inc. (NASDAQ:AGEN) announced a 1-for-20 reverse stock split effective April 12, 2024, to increase its per share trading price for Nasdaq listing and Russell Indices inclusion. The split affects all shares uniformly, maintaining the same percentage interest for stockholders, except for fractional shares which will be compensated in cash.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 8:33 pm

HOWL

Werewolf Therapeutics, Inc. (HOWL) presented preclinical results at AACR 2024 showing anti-tumor effects of WTX-518 and WTX-712, engineered to stimulate the immune system for cancer treatment. WTX-518 led to complete tumor regressions in models, while WTX-712 showed potent antitumor activity with a unique immune activation mechanism. The company aims to develop these as immunotherapies for refractory or immunologically unresponsive tumors.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 8:32 pm